Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BurGER study of burosumab in adults with X-linked hypophosphatemia in Germany
2019-003190-26Phase 3Completed
- Sponsor
- Julius-Maximilians-Universität Würzburg
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH), sponsored by Julius-Maximilians-Universität Würzburg. Primary endpoint: Mean serum phosphorus normalization. Started Oct 2020; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on 2019-003190-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003190-26.